Large-dose Hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with Hydroxyethyl starch 200/0.5 at recommended doses
Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not...
Gespeichert in:
| Veröffentlicht in: | Anesthesiology (Philadelphia) 2003-07, Vol.99 (1), p.42-47 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 47 |
|---|---|
| container_issue | 1 |
| container_start_page | 42 |
| container_title | Anesthesiology (Philadelphia) |
| container_volume | 99 |
| creator | KASPER, Stefan-Mario MEINERT, Philipp KAMPE, Sandra GÖRG, Christoph GEISEN, Christof MEHLHORN, Uwe DIEFENBACH, Christoph |
| description | Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not increase blood loss and transfusion requirements in elective coronary artery bypass surgery compared with 6% HES 200/0.5 at a dose of up to 33 ml/kg.
One hundred twenty adult patients scheduled for elective coronary artery bypass surgery were randomized to receive up to 50 ml/kg of 6% HES 130/0.4 or up to 33 ml/kg of 6% HES 200/0.5 for volume replacement during surgery and until 24 h thereafter. Volume requirements in excess of the respective maximum dose of HES were treated with gelatin. Colloid use was at the discretion of the attending physicians and not dictated by protocol. The primary outcome variable was chest tube drainage volume during the first 24 h after surgery.
The data from 117 patients (HES 130/0.4, 59 patients; HES 200/0.5, 58 patients) who completed the study according to protocol were analyzed. The median volumes of HES administered were 49 and 33 ml/kg in the HES 130/0.4 and HES 200/0.5 groups, respectively (P < 0.001). Consequently, patients in the HES 130/0.4 group required less gelatin in addition to HES than those in the HES 200/0.5 group (medians: 7 ml/kg vs. 20 ml/kg, P < 0.001). The combined volumes of HES and gelatin were similar for both groups (P = 0.21). The 24-h chest tube drainage (medians: 660 ml vs. 705 ml, P = 0.60) did not differ significantly between the groups, nor did transfusion outcome.
Six percent HES 130/0.4 at a median dose of 49 ml/kg did not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with 6% HES 200/0.5 at a median dose of 33 ml/kg. |
| doi_str_mv | 10.1097/00000542-200307000-00010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73401430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73401430</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-263f9b71780a308d5617f06bb4623a26a7e4a39ba30e4245e93554c7c18b4a3a3</originalsourceid><addsrcrecordid>eNptUU1v1DAQtRCIbgt_AfkCt7Tjj8TJEVVAK63EBc7RxJmwQUm8tR1Bfh7_jFm60AuW7NF43puvJ4RUcK2gcTdwOqXVhQYw4Ngp-Cp4Jnaq1HWhlCufix3_mcKA1hfiMqXv7LrS1C_FhdK1rmoLO_Frj_EbFX1IJO-2PoafG-XDNsmUMfqDVAZu4NrKPlCSS8hyXHwkZHQ3hdDLKaQkcelljrikYU1jWGSkh3WMNNOSExOkDzEsGDeJMRObbjsi09LKpdn1YT5ipF7-GPPhv13wmNxFKTFzboZz5p7xp67TK_FiwCnR67O9El8_fvhye1fsP3-6v32_L7xpVC50ZYamc8rVgAbqvqyUG6DqOltpg7pCRxZN03GQrLYlNaYsrXde1R0H0FyJd495jzE8rJRyO4_J0zThQmFNrTMWlDXAwPoR6CMvJ9LQHuM48_itgvYkX_tXvvaffO0f-Zj65lxj7Wbqn4hnvRjw9gzA5HEaeOl-TE842xgAfn4DDPekuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73401430</pqid></control><display><type>article</type><title>Large-dose Hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with Hydroxyethyl starch 200/0.5 at recommended doses</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KASPER, Stefan-Mario ; MEINERT, Philipp ; KAMPE, Sandra ; GÖRG, Christoph ; GEISEN, Christof ; MEHLHORN, Uwe ; DIEFENBACH, Christoph</creator><creatorcontrib>KASPER, Stefan-Mario ; MEINERT, Philipp ; KAMPE, Sandra ; GÖRG, Christoph ; GEISEN, Christof ; MEHLHORN, Uwe ; DIEFENBACH, Christoph</creatorcontrib><description>Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not increase blood loss and transfusion requirements in elective coronary artery bypass surgery compared with 6% HES 200/0.5 at a dose of up to 33 ml/kg.
One hundred twenty adult patients scheduled for elective coronary artery bypass surgery were randomized to receive up to 50 ml/kg of 6% HES 130/0.4 or up to 33 ml/kg of 6% HES 200/0.5 for volume replacement during surgery and until 24 h thereafter. Volume requirements in excess of the respective maximum dose of HES were treated with gelatin. Colloid use was at the discretion of the attending physicians and not dictated by protocol. The primary outcome variable was chest tube drainage volume during the first 24 h after surgery.
The data from 117 patients (HES 130/0.4, 59 patients; HES 200/0.5, 58 patients) who completed the study according to protocol were analyzed. The median volumes of HES administered were 49 and 33 ml/kg in the HES 130/0.4 and HES 200/0.5 groups, respectively (P < 0.001). Consequently, patients in the HES 130/0.4 group required less gelatin in addition to HES than those in the HES 200/0.5 group (medians: 7 ml/kg vs. 20 ml/kg, P < 0.001). The combined volumes of HES and gelatin were similar for both groups (P = 0.21). The 24-h chest tube drainage (medians: 660 ml vs. 705 ml, P = 0.60) did not differ significantly between the groups, nor did transfusion outcome.
Six percent HES 130/0.4 at a median dose of 49 ml/kg did not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with 6% HES 200/0.5 at a median dose of 33 ml/kg.</description><identifier>ISSN: 0003-3022</identifier><identifier>EISSN: 1528-1175</identifier><identifier>DOI: 10.1097/00000542-200307000-00010</identifier><identifier>PMID: 12826840</identifier><identifier>CODEN: ANESAV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Aged ; Anesthesia ; Anesthesia depending on type of surgery ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Coagulation Tests ; Blood Loss, Surgical - physiopathology ; Blood Transfusion ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Coronary Artery Bypass ; Erythrocyte Transfusion ; Female ; Humans ; Hydroxyethyl Starch Derivatives - administration & dosage ; Hydroxyethyl Starch Derivatives - adverse effects ; Hydroxyethyl Starch Derivatives - therapeutic use ; Intraoperative Period ; Male ; Medical sciences ; Middle Aged ; Plasma Substitutes - administration & dosage ; Plasma Substitutes - adverse effects ; Plasma Substitutes - therapeutic use ; Thoracic and cardiovascular surgery. Cardiopulmonary bypass ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Anesthesiology (Philadelphia), 2003-07, Vol.99 (1), p.42-47</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-263f9b71780a308d5617f06bb4623a26a7e4a39ba30e4245e93554c7c18b4a3a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14930049$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12826840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KASPER, Stefan-Mario</creatorcontrib><creatorcontrib>MEINERT, Philipp</creatorcontrib><creatorcontrib>KAMPE, Sandra</creatorcontrib><creatorcontrib>GÖRG, Christoph</creatorcontrib><creatorcontrib>GEISEN, Christof</creatorcontrib><creatorcontrib>MEHLHORN, Uwe</creatorcontrib><creatorcontrib>DIEFENBACH, Christoph</creatorcontrib><title>Large-dose Hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with Hydroxyethyl starch 200/0.5 at recommended doses</title><title>Anesthesiology (Philadelphia)</title><addtitle>Anesthesiology</addtitle><description>Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not increase blood loss and transfusion requirements in elective coronary artery bypass surgery compared with 6% HES 200/0.5 at a dose of up to 33 ml/kg.
One hundred twenty adult patients scheduled for elective coronary artery bypass surgery were randomized to receive up to 50 ml/kg of 6% HES 130/0.4 or up to 33 ml/kg of 6% HES 200/0.5 for volume replacement during surgery and until 24 h thereafter. Volume requirements in excess of the respective maximum dose of HES were treated with gelatin. Colloid use was at the discretion of the attending physicians and not dictated by protocol. The primary outcome variable was chest tube drainage volume during the first 24 h after surgery.
The data from 117 patients (HES 130/0.4, 59 patients; HES 200/0.5, 58 patients) who completed the study according to protocol were analyzed. The median volumes of HES administered were 49 and 33 ml/kg in the HES 130/0.4 and HES 200/0.5 groups, respectively (P < 0.001). Consequently, patients in the HES 130/0.4 group required less gelatin in addition to HES than those in the HES 200/0.5 group (medians: 7 ml/kg vs. 20 ml/kg, P < 0.001). The combined volumes of HES and gelatin were similar for both groups (P = 0.21). The 24-h chest tube drainage (medians: 660 ml vs. 705 ml, P = 0.60) did not differ significantly between the groups, nor did transfusion outcome.
Six percent HES 130/0.4 at a median dose of 49 ml/kg did not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with 6% HES 200/0.5 at a median dose of 33 ml/kg.</description><subject>Aged</subject><subject>Anesthesia</subject><subject>Anesthesia depending on type of surgery</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation Tests</subject><subject>Blood Loss, Surgical - physiopathology</subject><subject>Blood Transfusion</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Coronary Artery Bypass</subject><subject>Erythrocyte Transfusion</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives - administration & dosage</subject><subject>Hydroxyethyl Starch Derivatives - adverse effects</subject><subject>Hydroxyethyl Starch Derivatives - therapeutic use</subject><subject>Intraoperative Period</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Plasma Substitutes - administration & dosage</subject><subject>Plasma Substitutes - adverse effects</subject><subject>Plasma Substitutes - therapeutic use</subject><subject>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0003-3022</issn><issn>1528-1175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUU1v1DAQtRCIbgt_AfkCt7Tjj8TJEVVAK63EBc7RxJmwQUm8tR1Bfh7_jFm60AuW7NF43puvJ4RUcK2gcTdwOqXVhQYw4Ngp-Cp4Jnaq1HWhlCufix3_mcKA1hfiMqXv7LrS1C_FhdK1rmoLO_Frj_EbFX1IJO-2PoafG-XDNsmUMfqDVAZu4NrKPlCSS8hyXHwkZHQ3hdDLKaQkcelljrikYU1jWGSkh3WMNNOSExOkDzEsGDeJMRObbjsi09LKpdn1YT5ipF7-GPPhv13wmNxFKTFzboZz5p7xp67TK_FiwCnR67O9El8_fvhye1fsP3-6v32_L7xpVC50ZYamc8rVgAbqvqyUG6DqOltpg7pCRxZN03GQrLYlNaYsrXde1R0H0FyJd495jzE8rJRyO4_J0zThQmFNrTMWlDXAwPoR6CMvJ9LQHuM48_itgvYkX_tXvvaffO0f-Zj65lxj7Wbqn4hnvRjw9gzA5HEaeOl-TE842xgAfn4DDPekuw</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>KASPER, Stefan-Mario</creator><creator>MEINERT, Philipp</creator><creator>KAMPE, Sandra</creator><creator>GÖRG, Christoph</creator><creator>GEISEN, Christof</creator><creator>MEHLHORN, Uwe</creator><creator>DIEFENBACH, Christoph</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030701</creationdate><title>Large-dose Hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with Hydroxyethyl starch 200/0.5 at recommended doses</title><author>KASPER, Stefan-Mario ; MEINERT, Philipp ; KAMPE, Sandra ; GÖRG, Christoph ; GEISEN, Christof ; MEHLHORN, Uwe ; DIEFENBACH, Christoph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-263f9b71780a308d5617f06bb4623a26a7e4a39ba30e4245e93554c7c18b4a3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Anesthesia</topic><topic>Anesthesia depending on type of surgery</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation Tests</topic><topic>Blood Loss, Surgical - physiopathology</topic><topic>Blood Transfusion</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Coronary Artery Bypass</topic><topic>Erythrocyte Transfusion</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives - administration & dosage</topic><topic>Hydroxyethyl Starch Derivatives - adverse effects</topic><topic>Hydroxyethyl Starch Derivatives - therapeutic use</topic><topic>Intraoperative Period</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Plasma Substitutes - administration & dosage</topic><topic>Plasma Substitutes - adverse effects</topic><topic>Plasma Substitutes - therapeutic use</topic><topic>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KASPER, Stefan-Mario</creatorcontrib><creatorcontrib>MEINERT, Philipp</creatorcontrib><creatorcontrib>KAMPE, Sandra</creatorcontrib><creatorcontrib>GÖRG, Christoph</creatorcontrib><creatorcontrib>GEISEN, Christof</creatorcontrib><creatorcontrib>MEHLHORN, Uwe</creatorcontrib><creatorcontrib>DIEFENBACH, Christoph</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anesthesiology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KASPER, Stefan-Mario</au><au>MEINERT, Philipp</au><au>KAMPE, Sandra</au><au>GÖRG, Christoph</au><au>GEISEN, Christof</au><au>MEHLHORN, Uwe</au><au>DIEFENBACH, Christoph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Large-dose Hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with Hydroxyethyl starch 200/0.5 at recommended doses</atitle><jtitle>Anesthesiology (Philadelphia)</jtitle><addtitle>Anesthesiology</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>99</volume><issue>1</issue><spage>42</spage><epage>47</epage><pages>42-47</pages><issn>0003-3022</issn><eissn>1528-1175</eissn><coden>ANESAV</coden><abstract>Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not increase blood loss and transfusion requirements in elective coronary artery bypass surgery compared with 6% HES 200/0.5 at a dose of up to 33 ml/kg.
One hundred twenty adult patients scheduled for elective coronary artery bypass surgery were randomized to receive up to 50 ml/kg of 6% HES 130/0.4 or up to 33 ml/kg of 6% HES 200/0.5 for volume replacement during surgery and until 24 h thereafter. Volume requirements in excess of the respective maximum dose of HES were treated with gelatin. Colloid use was at the discretion of the attending physicians and not dictated by protocol. The primary outcome variable was chest tube drainage volume during the first 24 h after surgery.
The data from 117 patients (HES 130/0.4, 59 patients; HES 200/0.5, 58 patients) who completed the study according to protocol were analyzed. The median volumes of HES administered were 49 and 33 ml/kg in the HES 130/0.4 and HES 200/0.5 groups, respectively (P < 0.001). Consequently, patients in the HES 130/0.4 group required less gelatin in addition to HES than those in the HES 200/0.5 group (medians: 7 ml/kg vs. 20 ml/kg, P < 0.001). The combined volumes of HES and gelatin were similar for both groups (P = 0.21). The 24-h chest tube drainage (medians: 660 ml vs. 705 ml, P = 0.60) did not differ significantly between the groups, nor did transfusion outcome.
Six percent HES 130/0.4 at a median dose of 49 ml/kg did not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with 6% HES 200/0.5 at a median dose of 33 ml/kg.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>12826840</pmid><doi>10.1097/00000542-200307000-00010</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-3022 |
| ispartof | Anesthesiology (Philadelphia), 2003-07, Vol.99 (1), p.42-47 |
| issn | 0003-3022 1528-1175 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73401430 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Anesthesia Anesthesia depending on type of surgery Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Coagulation Tests Blood Loss, Surgical - physiopathology Blood Transfusion Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Coronary Artery Bypass Erythrocyte Transfusion Female Humans Hydroxyethyl Starch Derivatives - administration & dosage Hydroxyethyl Starch Derivatives - adverse effects Hydroxyethyl Starch Derivatives - therapeutic use Intraoperative Period Male Medical sciences Middle Aged Plasma Substitutes - administration & dosage Plasma Substitutes - adverse effects Plasma Substitutes - therapeutic use Thoracic and cardiovascular surgery. Cardiopulmonary bypass Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Large-dose Hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with Hydroxyethyl starch 200/0.5 at recommended doses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T04%3A56%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Large-dose%20Hydroxyethyl%20starch%20130/0.4%20does%20not%20increase%20blood%20loss%20and%20transfusion%20requirements%20in%20coronary%20artery%20bypass%20surgery%20compared%20with%20Hydroxyethyl%20starch%20200/0.5%20at%20recommended%20doses&rft.jtitle=Anesthesiology%20(Philadelphia)&rft.au=KASPER,%20Stefan-Mario&rft.date=2003-07-01&rft.volume=99&rft.issue=1&rft.spage=42&rft.epage=47&rft.pages=42-47&rft.issn=0003-3022&rft.eissn=1528-1175&rft.coden=ANESAV&rft_id=info:doi/10.1097/00000542-200307000-00010&rft_dat=%3Cproquest_cross%3E73401430%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73401430&rft_id=info:pmid/12826840&rfr_iscdi=true |